Is Zydus Lifesciences a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Zydus Lifesciences Ltd is a good quality company .

Is Zydus Lifesciences undervalued or overvalued?

The key valuation ratios of Zydus Lifesciences Ltd's currently when compared to its past seem to suggest it is in the Fair zone .

What is Zydus Lifesciences share price return in the past 10 years?

Zydus Lifesciences Ltd share price has appreciated 12.4% annually (CAGR) over the past ten years.

Is Zydus Lifesciences a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Zydus Lifesciences Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

Zydus Lifesciences Ltd - Stock Valuation and Financial Performance

Name: Zydus Lifesciences
Brand: Zydus Lifesciences

BSE: 532321 | NSE: ZYDUSLIFE | Pharmaceuticals & Drugs | Large Cap

Place order

Zydus Lifesciences Share Price

₹973.90 -11.80 -1.20%
as on 20-Dec'24 16:59

10 Year X-Ray of Zydus Lifesciences:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	23.2%	28.6%	16.5%	18.6%	15.9%	10%	14.4%	15.3%	13.6%	24.9%	-
Value Creation Index ⓘ	1.1	1.5	0.5	0.7	0.4	-0.1	0.3	0.4	0.2	1.2	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	8,651	9,427	9,377	11,905	13,166	14,253	14,404	15,110	17,237	19,547	20,870
Sales YoY Gr.	-	9%	-0.5%	27%	10.6%	8.3%	1.1%	4.9%	14.1%	13.4%	-
Adj EPS ⓘ	11.3	18.9	14.4	17.4	18.2	11.9	22.5	20.1	21.5	37.6	42.8
YoY Gr.	-	67.9%	-23.6%	20.6%	4.3%	-34.5%	89.5%	-11%	7.1%	74.9%	-
BVPS (₹) ⓘ	41.5	55.7	68	85.4	101.4	101.3	126.9	166	173.1	197.1	216.9
Adj Net Profit ⓘ	1,153	1,936	1,478	1,782	1,859	1,217	2,307	2,054	2,174	3,780	4,303
Cash Flow from Ops. ⓘ	994	1,894	1,312	919	1,282	2,932	3,294	2,105	2,689	3,228	-
Debt/CF from Ops. ⓘ	2.7	1.3	4	5.9	6.2	2.7	1.4	2	0.4	0.2	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	9.5%	8.2%	10.7%	13.4%
Adj EPS ⓘ	14.3%	15.7%	18.6%	74.9%
BVPSⓘ	18.9%	14.2%	15.8%	13.9%
Share Price	12.4%	29.6%	27.7%	43.2%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	30	38.9	23.4	22.7	19.4	11.7	19.7	13.7	12.6	20.3	20.7
Op. Profit Mgn % ⓘ	20.3	24.7	20.3	23.9	22.7	19.6	23.6	21	20.7	27.1	29.9
Net Profit Mgn % ⓘ	13.7	20.4	15.7	14.7	14.1	8.5	16	14.2	12.8	19.3	20.6
Debt to Equity ⓘ	0.6	0.4	0.8	0.6	0.8	0.8	0.4	0.3	0.1	0	0
Working Cap Days ⓘ	153	158	178	185	213	210	103	107	102	97	101
Cash Conv. Cycle ⓘ	61	53	63	80	101	103	10	18	20	24	55

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 20.70%

Sales growth is growing at healthy rate in last 3 years 10.72%

Net Profit is growing at healthy rate in last 3 years 18.58%

Sales growth is good in last 4 quarters at 13.69%

No data to display

Latest Financials - Zydus Lifesciences Ltd.

	Standalone	Consolidated
TTM EPS (₹)	43.2	42.8
TTM Sales (₹ Cr.)	11,945	20,870
BVPS (₹.) ⓘ	177.9	216.9
Reserves (₹ Cr.) ⓘ	18,107	21,724
P/BV ⓘ	5.48	4.49
PE ⓘ	22.55	22.77

From the Market
52 Week Low / High (₹)	648.05 / 1323.90
All Time Low / High (₹)	5.53 / 1323.90
Market Cap (₹ Cr.)	97,997
Equity (₹ Cr.)	100.6
Face Value (₹)	1
Industry PE ⓘ	44.3

Management X-Ray of Zydus Lifesciences:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Zydus Lifesciences

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Zydus Lifesciences

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	8,651	9,427	9,377	11,905	13,166	14,253	14,404	15,110	17,237	19,547
Operating Expenses ⓘ	6,897	7,097	7,472	9,058	10,187	11,473	11,018	11,935	13,666	14,248
Manufacturing Costs	1,282	1,553	1,130	1,892	2,155	2,483	2,503	2,572	2,983	3,124
Material Costs	2,814	2,673	3,065	3,657	4,141	4,243	4,094	4,757	5,336	5,260
Employee Cost	1,097	1,119	1,485	1,645	1,903	2,170	2,070	2,178	2,456	2,789
Other Costs ⓘ	1,705	1,752	1,792	1,864	1,988	2,577	2,352	2,429	2,890	3,075
Operating Profit ⓘ	1,754	2,330	1,904	2,847	2,978	2,780	3,385	3,175	3,572	5,299
Operating Profit Margin (%)	20.3%	24.7%	20.3%	23.9%	22.6%	19.5%	23.5%	21.0%	20.7%	27.1%
Other Income ⓘ	57	117	147	133	209	117	75	391	475	369
Interest ⓘ	68	53	63	111	196	342	186	127	130	81
Depreciation ⓘ	287	292	373	539	599	697	670	713	723	764
Exceptional Items ⓘ	-10	-3	0	0	-10	-364	-205	113	-604	-14
Profit Before Tax ⓘ	1,446	2,099	1,615	2,331	2,382	1,495	2,399	2,838	2,590	4,809
Tax ⓘ	259	177	129	564	530	320	194	512	588	978
Profit After Tax	1,186	1,921	1,486	1,766	1,852	1,176	2,206	2,326	2,002	3,831
PAT Margin (%)	13.7%	20.4%	15.8%	14.8%	14.1%	8.2%	15.3%	15.4%	11.6%	19.6%
Adjusted EPS (₹)	11.2	18.9	14.5	17.3	18.1	11.5	20.8	43.8	19.4	38.4
Dividend Payout Ratio (%)	21%	17%	22%	20%	19%	30%	17%	6%	31%	8%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	4,252	5,699	6,960	8,745	10,386	10,376	12,992	17,000	17,516	19,830
Share Capital ⓘ	102	102	102	102	102	102	102	102	101	101
Reserves ⓘ	4,149	5,597	6,858	8,642	10,284	10,273	12,890	16,897	17,415	19,729
Minority Interest	169	136	156	191	1293	1335	1937	2054	2173	2272
Debt	2,334	2,107	4,945	5,113	7,147	7,041	3,680	3,676	1,081	769
Long Term Debt	1,150	896	2,468	2,555	3,950	3,215	610	362	0	0
Short Term Debt	1,184	1,211	2,477	2,558	3,197	3,827	3,071	3,314	1,081	769
Trade Payables	1,091	1,308	1,548	1,888	1,923	2,044	2,206	2,138	2,125	2,127
Others Liabilities ⓘ	1,202	782	716	1,204	1,764	2,038	1,994	1,832	1,600	2,640
Total Liabilities ⓘ	9,047	10,032	14,325	17,141	22,513	22,834	22,810	26,700	24,494	27,637
Fixed Assets
Gross Block	5,139	5,767	8,103	9,349	15,702	16,782	17,345	17,651	18,344	19,920
Accumulated Depreciation	1,786	2,017	2,346	2,867	3,539	4,551	5,212	5,462	6,823	7,551
Net Fixed Assetsⓘ	3,352	3,751	5,757	6,483	12,164	12,231	12,133	12,189	11,521	12,369
CWIP ⓘ	798	951	1,543	1,527	837	742	783	726	1,201	2,423
Investmentsⓘ	154	416	435	746	674	765	830	3,288	1,547	1,221
Inventories	1,536	1,337	1,804	2,385	2,688	2,789	3,236	3,719	3,413	3,442
Trade Receivables	1,588	1,747	2,278	3,206	3,951	3,663	3,127	3,340	4,417	5,220
Cash Equivalents	670	639	1,544	1,315	549	965	888	1,107	573	1,105
Others Assetsⓘ	949	1,192	965	1,479	1,651	1,680	1,812	2,331	1,823	1,857
Total Assets ⓘ	9,047	10,032	14,325	17,141	22,513	22,834	22,810	26,700	24,494	27,637

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	994	1,894	1,312	919	1,282	2,932	3,294	2,105	2,689	3,228
PBT ⓘ	1,446	2,099	1,612	2,312	2,382	1,495	2,285	5,232	2,583	4,838
Adjustment ⓘ	345	250	334	624	539	1,474	1,163	-2,117	934	547
Changes in Working Capital ⓘ	-377	272	-411	-1384	-972	264	191	-336	-236	-871
Tax Paid ⓘ	-387	-646	-238	-602	-675	-303	-345	-675	-592	-1,286
Cash Flow From Investing Activity ⓘ	-465	-864	-2,872	-974	-4,239	-1,012	-725	-1,000	1,535	-1,475
Capex	-496	-957	-2,935	-1,035	-1,046	-889	-847	-1,055	-992	-883
Net Investments	-11	16	5	12	-4,746	29	-39	-2,863	2,298	-419
Others ⓘ	42	78	58	50	1,554	-152	161	2,918	229	-173
Cash Flow From Financing Activityⓘ	-351	-935	2,316	52	1,885	-1,528	-2,548	-868	-4,400	-1,810
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	987	0	0	0
Net Proceeds from Borrowing ⓘ	-330	-237	1,499	101	1,808	-786	-2,568	-674	-841	-83
Interest Paid ⓘ	-67	-44	-56	-105	-80	-324	-184	-111	-126	-73
Dividend Paid ⓘ	-184	-572	-327	0	-358	-715	-2	-372	-267	-621
Others ⓘ	230	-82	1,199	56	514	296	-781	289	-3,166	-1,034
Net Cash Flow ⓘ	178	95	756	-3	-1,072	391	22	236	-177	-58

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	30.85	38.62	23.47	22.5	19.36	11.32	18.88	15.51	11.6	20.52
ROCE (%)	23.21	28.6	16.52	18.55	15.89	10.02	14.38	15.3	13.64	24.9
Asset Turnover Ratio	1.03	1.01	0.79	0.76	0.66	0.63	1.27	1.19	1.32	1.46
PAT to CFO Conversion(x)	0.84	0.99	0.88	0.52	0.69	2.49	1.49	0.9	1.34	0.84
Working Capital Days
Receivable Days	56	63	77	84	99	97	43	40	42	46
Inventory Days	60	55	60	64	70	70	38	43	38	33
Payable Days	130	164	170	171	168	171	189	167	146	148

Zydus Lifesciences Ltd Stock News

Zydus Lifesciences Ltd FAQs

What is the share price of Zydus Lifesciences?

Company share prices are keep on changing according to the market conditions. The closing price of Zydus Lifesciences on 20-Dec-2024 16:59 is ₹973.9.

What is the market cap of Zydus Lifesciences?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 20-Dec-2024 16:59 the market cap of Zydus Lifesciences stood at ₹97,997.1.

What is the P/E ratio of Zydus Lifesciences?

The latest P/E ratio of Zydus Lifesciences as of 20-Dec-2024 16:59 is 22.55.

What is the P/B ratio of Zydus Lifesciences?

The latest P/B ratio of Zydus Lifesciences as of 20-Dec-2024 16:59 is 5.48.

What is the 52-week high and low of Zydus Lifesciences?

The 52-week high of Zydus Lifesciences is ₹1,323.9 and the 52-week low is ₹648.0.

What is the TTM revenue of Zydus Lifesciences?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Zydus Lifesciences is ₹11,945 ( Cr.) .

About Zydus Lifesciences Ltd

Cadila Healthcare Limited, a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products. The product portfolio of the company includes Active Pharmaceutical Ingredients (API) and human formulations. The company’s shares are listed on the National Stock Exchange of India Limited (NSE) and BSE Limited.

The company’s initiatives in the areas of research and development span across the pharmaceuticals value chain, including New Chemical Entities (NCE), biologics, vaccines, specialty and complex generic formulations and API process development. The company has a global presence and sells its products in the United States, India, Europe and emerging markets including countries in Latin America, Asia Pacific region and Africa. The company has a pool of modern, cost efficient and regulatory compliant manufacturing facilities which ensures continuous supply of high quality products at the most competitive prices to its customers across the globe.

Business area of the company

The company is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain of innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), active pharmaceutical ingredients (APIs), animal healthcare products and consumer wellness products. Innovation is the backbone of the company as it ensures business sustainability through continuous availability of new products for various businesses.

Business verticals / products

Human Health Formulations
Consumer Wellness
Animal Healthcare

Awards

2008-09:

The Company received the 'Social and Corporate Governance Awards 2008' in the 'Best Social Responsibility Practice' category presented by the BSE, NASSCOM Foundation and Times Foundation jointly.

2009-10:

Received the 'IMAI OE Award for the Pioneering and Paradigm Shifting Applications of OE in Tablet Manufacturing' by the KAIZEN Institute.
Received the 'Best-In-Class Manufacturing Award (Pharma Sector)' by Stars of the Industry Awards.

2010-11:

Declared the ‘Emerging Company of the Year’ by the Economic Times Awards for Corporate Excellence 2010.

2011-12:

Zydus Research Centre, Ahmedabad has achieved the full AAALAC accreditation for the fourth year in a row. It has also received accreditation from College of American Pathologists (CAP) upon completion of the inspection process. This accreditation was received in the first inspection itself.

2012-13:

The Gujarat Ecology Commission selected the Company for good ‘Environment-friendly Practices in Gujarat’. Zydus Research Centre won the Safety Award for the third consecutive year from Gujarat Safety Council.

2013-14:

Moraiya formulations facility was awarded the 'Gold Award - Pharma Sector, Mega Large Business' by The Economic Times and Frost & Sullivan for achieving operational excellence.

2014-15:

The Moraiya formulations facility was awarded the 'Green Manufacturing Award - Gold Category' by International Research Institute for Manufacturing.
The Baddi formulations facility was awarded 'Gold Certificate Merit' in IMEA - India Manufacturing Excellence Awards 2014 by The Economic Times in partnership with Frost & Sullivan.

2015-16:

It was awarded the Overall India Pharma Excellence Award and the India Pharma Innovation of the Year Award from the Department of Pharmaceuticals, Government of India.

2016-17:

Topical formulations facility received the ‘Silver Certificate of Merit’ from Frost & Sullivan at India Manufacturing Excellence Awards 2016.

2017-18:

The manufacturing sites at Moraiya, Baddi and Sikkim received the Silver medal at the National Award for Manufacturing Competitiveness (NAMC) by IRIM global.
API manufacturing facility at Ankleshwar Ank Unit I bagged a Silver at the Greentech Safety Award 2017 in recognition of its safety systems from the Greentech Foundation, Environment.

2018-19:

Moraiya formulations manufacturing facility received the Gold Award in the category of Pharma Sector, Large Business at the India Manufacturing Excellence Awards, 2018.

2019-20: